New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
09:13 EDTPCYCPharmacyclics price target raised to $165 from $110 at Wedbush
Wedbush raised its price target to $165 for Pharmacyclics on expectations breakthrough designation in MCL will lead to an earlier than expected approval for ibrutinib. The firm also expects significant off-label use of ibrutinib across hematological malignancies and keeps an Outperform rating on shares of Pharmacyclics.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
08:05 EDTPCYCPharmacyclics files supplemental new drug application for Imbruvica
Pharmacyclics announced that it has submitted a supplemental New Drug Application to the FDA, based on data from the randomized, multi-center, open-label Phase III Resonatetm study, PCYC-1112, a head-to-head comparison of single agent Imbruvicatm versus ofatumumab in 391 patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, who had received at least one prior therapy. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use